Compare LMB & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | CTKB |
|---|---|---|
| Founded | 1901 | 1990 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.3M | 541.1M |
| IPO Year | 2014 | 2021 |
| Metric | LMB | CTKB |
|---|---|---|
| Price | $47.75 | $5.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $75.00 | $5.56 |
| AVG Volume (30 Days) | 200.8K | ★ 1.3M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $646,804,000.00 | $193,015,000.00 |
| Revenue This Year | $23.64 | $3.94 |
| Revenue Next Year | $19.79 | $6.59 |
| P/E Ratio | $63.47 | ★ N/A |
| Revenue Growth | ★ 24.68 | 17.67 |
| 52 Week Low | $40.74 | $3.31 |
| 52 Week High | $114.95 | $6.21 |
| Indicator | LMB | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 51.62 |
| Support Level | $40.74 | $4.17 |
| Resistance Level | $52.34 | $6.21 |
| Average True Range (ATR) | 1.87 | 0.30 |
| MACD | -0.26 | -0.04 |
| Stochastic Oscillator | 2.68 | 30.04 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.